The Intellectual Property & Science business of Thomson Reuters has announced that The Roche Group, a provider of pharmaceutical and diagnostic products and services, has selected Thomson IP Manager to manage the organisation's expanding international patent portfolio. Thomson IP Manager, a premier intellectual asset management (IAM) software solution, will improve company-wide IP work processes and collaboration across the organisation.
Headquartered in Switzerland, Roche is a research-focused company, discovering, developing and providing innovative diagnostic and therapeutic products and services to patients and healthcare professionals worldwide. With twelve patent group sites in Asia, Europe and the US, Roche needs a global solution that will allow it to efficiently and effectively manage its valuable IP asset portfolio, which grows by nearly 500 rights annually.
Roche initiated a global patent group project, taking a democratic approach as part of its selection process. Patent and law professionals evaluated several high-potential IAM software solutions before making the decision to use Thomson IP Manager.
According to Karin Bruehlmann, Head of Controlling, IT & Services Group Patents, The Roche Group, Roche also will utilise the Thomson IP Manager integrated Data Validation Service to proactively identify and correct data discrepancies in their patent portfolio, comparing data against the Thomson Reuters Global Patent Collection. This comprehensive database comprises over 76 million patents for more than 70 issuing authorities. It ensures errors that could affect critical prosecution and maintenance dates can be quickly caught and fixed, reducing the risk of lost rights and costly delays.
